Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

Eli Lilly’s retatrutide, a triple hormone receptor agonist for obesity, has produced some of the strongest weight-loss data yet, with up to around 26.6% placebo-adjusted reduction in body weight in late-stage trials.1

Earlier obesity studies reported that up to roughly 29% body weight reduction and around 23.7% of patients achieving ≥35% weight loss on the 12 mg dose set a new benchmark for obesity therapies.2

In addition to weight loss, retatrutide significantly reduced knee osteoarthritis pain by about 75% in one trial, adding potential benefits beyond weight control.1

In the Phase III *TRIUMPH-4 trial, an unusual safety signal emerged:*
a form of abnormal skin sensation (dysesthesia), described as an abnormal sense of touch.1

This dysesthesia signal was not prominent in earlier Phase II data, so analysts had expected a safety profile closer to earlier stages, making the new finding particularly notable for ongoing safety evaluation.1

Despite the new side-effect signal, the overall efficacy profile of retatrutide has strengthened Lilly’s obesity pipeline and set a new efficacy bar among incretin-based weight-loss drugs.12

Sources:

1. https://www.biospace.com/drug-development/lillys-retatrutide-scores-triple-trial-triumph-with-26-weight-loss-but-new-safety-signal-emerges

2. https://pharmaphorum.com/news/lillys-obesity-triple-pulls-29-weight-loss-trial